Financings in Brief: Nanogen
This article was originally published in The Gray Sheet
Executive Summary
Nanogen: Diagnostics developer plans an initial public offering of up to $40 mil. in common stock. A preliminary prospectus filed with the Securities and Exchange Commission does not specify the anticipated price per share or number of shares to be offered. San Diego-based Nanogen is developing a fully automated, microelectronics-based platform technology for rapid identification and analysis of test samples containing charged molecules, which incorporates a laser-based fluorescence scanner to detect molecular binding. The system has broad commercial applicability in the fields of medical diagnostics, biomedical research, genomics, genetic testing and drug discovery, Nanogen maintains. The firm has a May 1997 joint venture with Becton Dickinson for development of infectious disease diagnostics based on the technology. Separate collaborative agreements signed in December with Hoechst and Elan cover development of drug discovery tools and genomic research applications, respectively.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.